Roche’s New Pharma Head Vows To Expand Development Of Targeted Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Daniel O’Day, new pharma head at Roche, aims to increase the proportion of medicines developed together with diagnostic tests, underscoring the rising importance and success of personal health care.
You may also be interested in...
Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him
O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.
AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division
AstraZeneca has appointed an experienced biotech and pharmaceuticals executive, Pascal Soriot, to its vacant CEO position, while Roche switches Daniel O'Day from its diagnostics to its pharmaceuticals division.
Genentech Resubmits T-DM1 To FDA, This Time With An Overall Survival Benefit
The antibody drug conjugate showed a significant overall survival benefit in HER2-positive metastatic breast cancer in the EMILIA trial, the company announced.